Actively Recruiting

Phase Not Applicable
Age: 70Years - 130Years
All Genders
NCT05720910

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Led by Institut Bergonié · Updated on 2026-01-15

720

Participants Needed

10

Research Sites

128 weeks

Total Duration

On this page

Sponsors

I

Institut Bergonié

Lead Sponsor

E

EUCLID Clinical Trial Platform

Collaborating Sponsor

AI-Summary

What this Trial Is About

The primary objective of GERONTE STUDY is to evaluate the effectiveness of the GERONTE, ICT-based, integrated care pathway to improve patient 6-month quality of life, in France. Study design is a stepped wedge randomised controlled trial. Clusters will be participating hospitals, comprising eight investigating sites in total (Figure 2). This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. The primary endpoint is the Quality of Life assessed by the EORTC QLQ-C30 (version 3.0) questionnaire at 6 months after GERONTE implementation. It has 3 sub-scores that will be analysed independently, with alpha risk adjustment.

CONDITIONS

Official Title

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Who Can Participate

Age: 70Years - 130Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 70 years or older
  • New or progressive breast, lung, colorectal, or prostate cancer confirmed by histology or strong clinical suspicion
  • Estimated life expectancy greater than 6 months
  • At least one moderate or severe additional health condition besides the current cancer
  • Willing and able to comply with study procedures
  • Signed informed consent before any study procedure
  • Completed baseline Quality of Life questionnaire (EORTC QLQ-C30)
  • Affiliated with French social security according to French biomedical research law
  • Specific tumor criteria depending on cancer type and stage, including treatment considerations by cancer specialists
  • For breast cancer: non-metastatic with planned surgery/radiotherapy/chemotherapy, or metastatic with limited prior chemotherapy
  • For colorectal cancer: non-metastatic with no prior therapy at recruiting hospital and planned surgery/radiotherapy/chemotherapy/immunotherapy, or metastatic with first or second line systemic therapy planned
  • For lung cancer: non-metastatic or metastatic with planned surgery (excluding thermoablation alone), radiotherapy (excluding SBRT), or systemic therapy excluding certain monotherapies
  • For prostate cancer: non-metastatic or metastatic with planned radiotherapy, hormone therapy, or specified systemic treatments
Not Eligible

You will not qualify if you...

  • Mental illness or cognitive impairment limiting consent or trial participation
  • Participation in another interventional trial with non-registered anticancer drugs or geriatric intervention trial
  • Patient or caregiver unable or unwilling to use internet devices (tablet, computer, smartphone) as required
  • Prior inclusion in this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Centre Hospitalier de la Côte Basque

Bayonne, France, 64109

Actively Recruiting

2

Institut Bergonié

Bordeaux, France, 33076

Actively Recruiting

3

Centre Hospitalier Départemental Vendée

La Roche-sur-Yon, France, 85000

Actively Recruiting

4

Centre Léon Bérard

Lyon, France, 69373

Actively Recruiting

5

Centre Azuréen de Cancérologie

Mougins, France, 06250

Actively Recruiting

6

Centre Hospitalier Universitaire de Nice

Nice, France, 06000

Actively Recruiting

7

Centre Antoine Lacassagne

Nice, France, 06189

Actively Recruiting

8

Hôpital Tenon AP-HP

Paris, France, 75020

Actively Recruiting

9

Centre Eugène Marquis

Rennes, France, 35042

Actively Recruiting

10

Groupe Hospitalier Rance Emeraude

St-Malo, France, 35400

Actively Recruiting

Loading map...

Research Team

P

Pierre-Louis SOUBEYRAN, MD, PhD

CONTACT

S

Simone MATHOULIN-PELISSIER, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here